News | Health & Safety
29 Apr 2017 7:55
NZCity News
NZCity CalculatorReturn to NZCity

  • Start Page
  • Personalise
  • Sport
  • Weather
  • Olympic Games
  • Finance
  • Shopping
  • Jobs
  • Horoscopes
  • Lotto Results
  • Photo Gallery
  • Site Gallery
  • TVNow
  • Dating
  • SearchNZ
  • NZSearch
  • Crime.co.nz
  • RugbyLeague
  • Make Home
  • About NZCity
  • Contact NZCity
  • Your Privacy
  • Advertising
  • Login
  • Join for Free

  •   Home > News > Health & Safety

    Pacific Edge gets $3m extension to grant

    Pacific Edge has won a two-year extension to its research grant to fund the development of its Cxbladder products for bladder cancer detection.


    Pacific Edge has won a two-year extension to its Callaghan Innovation research grant to fund the development of its Cxbladder diagnostic suite of products for bladder cancer detection.

    The Dunedin-based firm has received up to $3 million of extra funding for research and development spread over two years, on top of an initial three-year grant of $4.5m it received in 2014, it said in a statement.

    Since the first grant was awarded, Pacific Edge has launched three new products to add to the original bladder cancer diagnostics test, with each test addressing different clinical needs.

    The shares rose 3.5 per cent to 59 cents.

    "Investment into research and development is a major focus for Pacific Edge and we are continually looking at how we can provide better and more targeted diagnostic tools for clinicians and their patients," chief executive David Darling said.

    "The Growth Grant supplements Pacific Edge's own investment into R&D and will enable us to bring new innovations through into new products and product improvements."

    The company raised $8 million in February through a share placement to institutional investors to shore up its balance sheet as it ramps up efforts to lift commercial growth.

    It started making commercial sales in 2013 and at the time was targeting $100m in gross revenue within five years.

    The recent capital raise left it with $9m of cash to fund its immediate growth needs, and when reporting its first half result in November it signalled plans to have all four Cxbladder products fully launched in the US by 2018.

    # (BusinessDesk receives funding from Callaghan Innovation to help cover the commercialisation of innovation.)


    NZN




    © 2017 NZN, NZCity


     Other Health & Safety News
     28 Apr: Hemp seeds to be allowed in food in NZ
     28 Apr: Superbug a 'serious threat' to Kiwis
     28 Apr: Ethnic differences in depression diagnosis
     25 Apr: Acupuncturist criticised over left needle
     20 Apr: Abano to sue biggest shareholder
     19 Apr: Reactions to mental health report
     19 Apr: Pharmac rejects funding tampons
     Top Stories

    RUGBY RUGBY
    Chiefs confident replacements can step up More...


    BUSINESS BUSINESS
    ACCC drops action against Fonterra More...



     Today's News

    Environment:
    Climate change march in Christchurch 7:36

    Rugby League:
    Rabbitohs booed by their own in Manly loss 7:26

    International:
    Donald Trump: Why do we care about the US President's first 100 days? 7:16

    Environment:
    Little spotted kiwi move to Auckland 7:16

    Accident and Emergency:
    Slip clearing in Manawatu Gorge continues 7:06

    Rugby League:
    Thurston missed as Eels beat Cowboys 6:26

    Soccer:
    The man who gets Sydney FC ready to wiggle 21:56

    Rugby League:
    Broncos' Milford named for Samoa Test 21:16

    Law and Order:
    Boy found safe in Newcastle after being taken from Brisbane's Lady Cilento Hospital 21:06

    Law and Order:
    Private funeral for Verity McLean 19:26


     News Search






    Power Search


    © 2017 New Zealand City Ltd